Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

What this trial studies

Primary Objectives: * To assess the excretion balance after oral and IV administration of \[14C\]-SAR439859 * To assess PK of total radioactivity, \[14C\] -SAR439859 and its metabolite (M7) after IV administration of \[14C\]-SAR439859 and, PK of radioactivity, SAR439859 and M7 after oral administration of SAR439859 alone or with \[14C\]-SAR439859 * To assess IV clearance and absolute bioavailability of SAR439859 using microdose of \[14C\]-SAR439859 tracer on top of a single tablet oral dose. * To assess relative bioavailability of SAR439859 given as tablet or solution Secondary objectives: * To collect samples in order to assess metabolic profile in plasma and excreta of SAR439859 after oral administration of \[14C\]-SAR439859 as solution, contribution in plasma of SAR439859 and metabolite relative to total radioactivity and identify metabolites (samples will be analyzed according to metabolic analysis plan and results will be documented in a separate report). * To assess safety and tolerance of SAR439859

Conditions in scope

• Breast Cancer
• Healthy Volunteers

Interventions

• amcenestrant (Drug) — Tablet Oral
• [14C]-SAR439859 microtracer (Drug) — Solution for infusion Intravenous
• [14C]-SAR439859 (Drug) — Powder for oral solution Oral

Who can join

Women only · Ages 40 Years to 75 Years · Accepts healthy volunteers.

Inclusion criteria

• Female participants (age between 40 and 75 years old) who are postmenopausal or had post-bilateral surgical oophorectomy not linked to a history of cancer.
• Participants who are overtly healthy. Body weight within 40.0 and 95.0 kg and body mass index (BMI) within the range 18.0 and 30 kg/m2 (inclusive).
• Capable of giving signed informed consent.

Exclusion criteria

• Subject has clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.
• Subject who had severe course of COVID-19 (i.e., hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
• Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
• Blood donation, any volume (usually approximately 500 mL), within 2 months before inclusion.
• Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
• History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day).
• Smoking regularly more than 5 cigarettes or equivalent per week, unable to stop smoking during the study (occasional smoker can be enrolled).
• Excessive consumption of beverages containing xanthine bases (more than 5 cups or glasses per day).

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Completed
• Study type: Interventional
• Phase: PHASE1
• Start date: 2021-06-15
• Primary completion: 2021-08-19
• Last update posted: 2025-09-24
• First posted: 2021-06-25

Sponsor & contact

Lead sponsor: Sanofi (Industry)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administration (Day 1 to Day 6)
• Percentage of radioactive dose excreted in urine and feces after oral administration (Day 7 up to max Day 44)
• Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administration (Day 1 to Day 3)
  Area under the plasma concentration versus time curve extrapolated to infinity
• Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administration (Day 1 to Day 3)
  Terminal half-life associated with the terminal slope (λz)
• Assessment of PK parameter: CL for SAR439859 after IV administration (Day 1 to Day 3)
  Total body clearance

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.